Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Special Features of Adaptive Immunity01:20

Special Features of Adaptive Immunity

The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Does this patient with urticaria/angioedema have anaphylaxis?

Clinical medicine (London, England)·2011
Same author

Flow cytometric analysis of TCR Vβ repertoire in patients with 22q11.2 deletion syndrome.

Scandinavian journal of immunology·2011
Same author

Pattern recognition receptor expression is not impaired in patients with chronic mucocutanous candidiasis with or without autoimmune polyendocrinopathy candidiasis ectodermal dystrophy.

Clinical and experimental immunology·2009
Same author

Impaired dendritic cell maturation and cytokine production in patients with chronic mucocutanous candidiasis with or without APECED.

Clinical and experimental immunology·2008
Same author

Immune deficiency disorders involving neutrophils.

Journal of clinical pathology·2008
Same author

T cell receptor Vbeta repertoire of T lymphocytes and T regulatory cells by flow cytometric analysis in healthy children.

Clinical and experimental immunology·2007

Related Experiment Video

Updated: Jul 9, 2026

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype
08:49

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Published on: March 18, 2020

Common variable immunodeficiency: an update on therapeutic approaches.

C A Bethune1, G P Spickett

  • 1Regional Department of Immunology, Royal Victoria Infirmary, Newcastle upon Tyne, England.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|November 24, 2007
PubMed
Summary
This summary is machine-generated.

Common variable immunodeficiency (CVID) is a complex condition requiring tailored treatment. Optimal immunoglobulin replacement therapy is crucial, but gaps remain in understanding dosing and managing complications, impacting patient outcomes.

More Related Videos

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Whole Blood Assay with Dual Co-Stimulation for Antigen-Specific Analysis of Host Immunity to Fungal and Viral Pathogens
06:03

Whole Blood Assay with Dual Co-Stimulation for Antigen-Specific Analysis of Host Immunity to Fungal and Viral Pathogens

Published on: September 20, 2024

Related Experiment Videos

Last Updated: Jul 9, 2026

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype
08:49

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Published on: March 18, 2020

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Whole Blood Assay with Dual Co-Stimulation for Antigen-Specific Analysis of Host Immunity to Fungal and Viral Pathogens
06:03

Whole Blood Assay with Dual Co-Stimulation for Antigen-Specific Analysis of Host Immunity to Fungal and Viral Pathogens

Published on: September 20, 2024

Area of Science:

  • Immunology
  • Clinical Medicine
  • Pharmacology

Background:

  • Common variable immunodeficiency (CVID) is increasingly recognized as a heterogeneous disorder, complicating therapeutic assessments.
  • Current understanding of CVID management is challenged by its non-uniform nature, affecting historical data interpretation.

Purpose of the Study:

  • To review the evidence for optimal replacement immunoglobulin therapy in CVID.
  • To address key questions regarding immunoglobulin product properties, selection, adverse events, and infectious risks.
  • To discuss the management of organ-specific complications and antibiotic strategies in CVID.

Main Methods:

  • Review of existing scientific literature and clinical studies on CVID therapeutics.
  • Analysis of immunoglobulin product characteristics and their clinical implications.
  • Examination of treatment strategies for CVID-associated infections and organ complications.

Main Results:

  • Immunoglobulin replacement therapy remains the gold standard for CVID, though products are not interchangeable.
  • Unanswered questions persist regarding optimal immunoglobulin dosing and target IgG levels, especially for patients with lung disease.
  • Current antibiotic regimens may be ineffective for severe recurrent sinus disease, highlighting the need for better clinical trials.

Conclusions:

  • Despite advances, many CVID patients in the UK experience delayed diagnosis and suboptimal therapy, leading to preventable morbidity and mortality.
  • Further research and robust clinical trials are essential to refine CVID management strategies, including antibiotic use.
  • Personalized approaches are needed to address the heterogeneity of CVID and its diverse complications.